Immuno-Oncology Drugs Market - Insights
Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. It helps the immune system to recognize and target cancer cells. The therapy facilitates long term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology therapy works against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
Introduction of novel immune-oncology therapies with lesser side effects is driving growth of the global immune-oncology drugs market
Improved therapeutic outcomes have led to increasing success rates against cancer, owing to in-depth understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Moreover, immuno-oncology therapies have lesser side effects compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Immuno-oncology therapy operates through the immune system of the body and does not harm healthy cells as opposed to conventional therapies such as targeted therapy, chemotherapy, and radiation therapy that affect cancerous as well as healthy cells. Novel immune therapies can restore the ability of the immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Such immuno-oncology based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a, human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies have been further developed into conjugated monoclonal antibodies, which are combined with other agents such as radiolabeled antibodies and chemo labeled antibodies. Cancer vaccines have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapies is a new therapy emerging in the immuno-oncology such as CAR-T Cell Therapy under, which Kymriah and Yescarta are available.
The global immuno-oncology drugs market was valued at US$ 43,084.5 million in 2016 and is expected to witness a robust CAGR of 14.9% over the forecast period (2017 – 2025).
Figure No.1: Global Immuno-Oncology Drugs Market Share, by Region (%), 2016
Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune-oncology drugs market
According to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015. Owing to benefits associated with these therapies, the leading players are actively investing in research and development into this treatment category through various collaborations and individual research studies. For instance, EMD Serono is involved in research and development of immune-oncology drugs and has a few drugs in pipeline such as M7824 (investigational) bifunctional immunotherapy. In 2015, Merck & Co., a leading drug manufacturer and MD Anderson Cancer Center entered into a strategic clinical research collaboration for formers drug Keytruda (Pembrolizumab). Celsee Diagnostics and IncellDx announced an immuno-oncology research agreement in 2017. Bristol-Myers Squibb is developing immuno-oncology approaches for treatment of colorectal cancer, lung cancer, melanoma, liver cancer, lymphoma, multiple myeloma, and others. Amgen, Inc. is actively involved in immune-oncology research and the company launched an immunotherapy collaboration with Kite Pharma to develop and commercialize chimeric antigen receptor (CAR) T cells in 2015.
However, high cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.
Some major players operating in the immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.
Natural immunity system holds superior potential to specifically target and destruct tumors while avoiding harm to the normal healthy tissue along with long term memory to prevent cancer recurrence. Immuno-oncology research has supported the fact that immunity system can effectively identify tumors and can stop or control long term growth of the same through immunosurveillance. However, cancer progression leads to suppression of immunity systems natural functioning wherein immune-oncology therapies play an important role. Advent of innovative immune-oncology therapies such as immune-checkpoint inhibitors, therapeutic cancer vaccines, and CAR-T therapies has spurred leading organizations to actively invest into research and development. However, high costs associated with therapy is restraining growth of the immuno-oncology drugs market.
Global Immuno-oncology drugs market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc. and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost growth of the immuno-oncology drugs market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 25 market data tables and 38 figures on "Immuno-Oncology Drugs Market - Global forecast to 2025”
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.